Monday, Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935). SKYLINE (TAK-935-3001) study evaluated soticlestat plus standard of care versus placebo plus standard of care in patients with refractory Dravet syndrome. Soticlestat narrowly missed the primary endpoint of reduction from baseline in convulsive seizure frequency compared to placebo (p-value = 0.06). Also Read: Takeda’s Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement. Among the six key secondary endpoints, soticlestat showed clinically meaningful and nominally significant results in the responder rate, measures of caregiver and clinician global impression ...